[{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"ALT-100","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aqualung Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Aqualung Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Grapiprant","moa":"Aldose reductase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Applied Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Applied Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Celonic","sponsor":"Airway Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"AT-100","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Celonic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celonic \/ Airway Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Celonic \/ Airway Therapeutics"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"4D-710","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"4D Molecular Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.01,"dosageForm":"Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"5","companyTruncated":"4D Molecular Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PAO Group","sponsor":"Undiaclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"PAO Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"PAO Group \/ Undiaclosed","highestDevelopmentStatusID":"5","companyTruncated":"PAO Group \/ Undiaclosed"},{"orgOrder":0,"company":"ImmunoMet","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"IM156","moa":"Protein Complex 1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"ImmunoMet","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"ImmunoMet \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"ImmunoMet \/ Not Applicable"},{"orgOrder":0,"company":"PAO Group","sponsor":"CBD pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"PAO Group","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Liquid Extract","sponsorNew":"PAO Group \/ CBD pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"PAO Group \/ CBD pharmaceutical"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BioCardia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Mesenchymal Cell","moa":"NK-1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"BioCardia","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BioCardia \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioCardia \/ Not Applicable"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ALTA-2530","moa":"IL-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Sumitovant Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Altavant Sciences \/ Sumitovant Biopharma"},{"orgOrder":0,"company":"Altavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"ALTA-2530","moa":"IL-1","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altavant Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Altavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Altavant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Akari Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cells","moa":"Stem Cell proliferation","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vapendavir","moa":"Capsid binding","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Altesa Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Altesa Biosciences \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Altesa Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Tvardi Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"TTI-101","moa":"STAT3 protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Tvardi Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tvardi Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Tvardi Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cells","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"StemCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Umbilical Cord Blood Stem Cell Therapy","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"StemCyte","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"StemCyte \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"StemCyte \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell Therapy","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"CD103","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Breathe Biologics","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Demerger","leadProduct":"Umbilical Cord Derived Monocyte","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Breathe Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Breathe Biologics \/ Therapeutic Solutions","highestDevelopmentStatusID":"5","companyTruncated":"Breathe Biologics \/ Therapeutic Solutions"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cells","moa":"CD103","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"BioAegis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Plasma Gelsolin Therapy","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"BioAegis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BioAegis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"BioAegis Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Mesenchymal Stem Cell","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Chrysalis BioTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Rusalatide Acetate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Chrysalis BioTherapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chrysalis BioTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Chrysalis BioTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mannkind","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Nintedanib Esylate","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mannkind \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Mannkind \/ Not Applicable"},{"orgOrder":0,"company":"Alentis Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Lixudebart","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"IND Enabling","graph3":"Alentis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Alentis Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Alentis Therapeutics \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : JSP191 (briquilimab) is a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases. It is being evaluated for the treatment of Asthma.

                          Brand Name : JSP191

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : Briquilimab

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : ALE.F02 (Lixudebart) is a claudin 1 inhibitor ADC, which is currently being evaluated for the treatment of Idiopathic Pulmonary Fibrosis.

                          Brand Name : ALE.F02

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 29, 2024

                          Lead Product(s) : Lixudebart

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : The inhaled therapeutic candidate MNKD-201 (nintedanib) is being evaluated in early-stage clinical trial studies for treating patients suffering from pulmonary fibrotic diseases.

                          Brand Name : MNKD-201

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 30, 2024

                          Lead Product(s) : Nintedanib Esylate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : GRI-0621, a small molecule that inhibits the activity of human type 1, iNKT cells. It is being evaluated for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

                          Brand Name : GRI-0621

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 27, 2023

                          Lead Product(s) : GRI-0621

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Chrysalin (rusalatide acetate) is a natural regenerative peptide that accelerates tissue repair and revascularization while modulating the inflammatory response, which is investigated for Acute Respiratory Distress Syndrome.

                          Brand Name : Chrysalin

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 26, 2023

                          Lead Product(s) : Rusalatide Acetate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : JadiCell is a mesenchymal stem cell therapy led to preserving lung function and increasing “repair cell” production in mice with inflammation-induced lung injury in COPD patients.

                          Brand Name : JadiCell

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          March 13, 2023

                          Lead Product(s) : Mesenchymal Stem Cell

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Cosmoprof India
                          Not Confirmed